Reports that the dopamine agonist drug pramipexole dihydrochloride from Pharmacia & Upjohn and Boehringer Ingelheim Pharmaceuticals Inc. has been cleared for the treatment of idiopathic Parkinson's disease. Results of clinical trials; Dosage.EBSCO_AspModern Medicine...
METHODS OF ADMINSTERING AN AMPA RECEPTOR ANTAGONIST TO TREAT DYSKINESIAS ASSOCIATED WITH DOPAMINE AGONIST THERAPY Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.doi:US20010034345 A1...
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this... T Nissen,EJ Newman,KA Grosset,... - 《Scottish Medical Journal...
aPramipexole is a dopamine agonist indicated for Parkinson disease that has shown utility in the treatment of periodic leg movement disorder. 199 Recent studies suggest that this compound may improve both pain and sleep in fibromyalgia patients. 200 Pramipexole是为在周期性腿运动障碍的治疗显示了公共事...
aPramipexole is a dopamine agonist indicated for Parkinson disease that has shown utility in the treatment of periodic leg movement disorder.199 Recent studies suggest that this compound may improve both pain and sleep in fi-bromyalgia patients. 200 Pramipexole是为显示的帕金森疾病表明的多巴胺苦闷者公...
Continuous compensation for cerebral dopamine deficiency represents an ideal treatment for Parkinson’s disease. Dopamine does not cross the digestive and blood–brain barriers and is rapidly oxidized. The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an...
Glucagon-like peptide-1 receptor (GLP-1R) agonist has gained interest as a potential treatment for Parkinson's disease (PD). However, the exact mechanisms responsible for the therapeutic effects of GLP-1R-related agonists are not yet fully understood. Methods In this study, we explores the ...
摘要: Background Impulse control disorders (ICDs) encompass a wide spectrum of abnormal behaviour frequently found in cases of Parkinson's disease (PD) treated with dopamine agonists (DAs). The main aim of this study was to analyse ICD prevalence with different DAs.关键词:...
known as NeuroHIV. These data will improve our understanding of the interactions between the dopaminergic and immune systems during both homeostatic function and in disease, clarify the effects of existing dopaminergic drugs and promote the creation of new therapeutic strategies based on manipulating immu...
Cabergoline, already used successfully as a treatment for hyperprolactinaemic amenorrhoea and the inhibition of lactation, is now awaiting approval as a treatment for Parkinson’s disease. It is the first long-acting dopamine agonist to be developed for this indication. Treatment with cabergoline ...